ImmunoGenesis Doses First Patient in Phase 1a/1b Clinical Trial of IMGS‑001 in Relapsed or Refractory Advanced Solid Tumors by rpadmin | Sep 28, 2023 | ImmunoGenesis
ImmunoGenesis and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Trial of IMGS-001 for Relapsed or Refractory Advanced Solid Tumors by rpadmin | Aug 31, 2023 | ImmunoGenesis